Twist Bioscience Corporation (TWST) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2025-11-17
Business type: Asset play
How it makes money
It generates $376.6 million primarily from healthcare and chemical customers by replacing traditional plate-based synthesis with high-throughput DNA writing on silicon chips.
The company serves over 3,800 customers, with the healthcare sector contributing $215.1 million of its $376.6 million total revenue. It sells synthetic genes and tools for next-generation sequencing, utilizing a proprietary silicon platform to manufacture genetic material faster and at a lower cost than legacy methods.
Its revenue model is driven by the volume of synthetic DNA produced and the mix of products, ranging from simple fragments to more complex biopharma services for antibody discovery and development.
What protects it: the moat
Its proprietary silicon platform writes 1,000,000 pieces of DNA on a single chip, creating a cost and throughput advantage over legacy plate-based manufacturers.
The business relies on a proprietary technology that miniaturizes DNA synthesis reactions, allowing it to write over 1,000,000 oligonucleotides on a single silicon chip roughly the size of a mobile phone. This miniaturization reduces the volume of expensive chemicals required for synthesis compared to traditional plate-based methods.
Management claims this integrated platform—combining hardware, software, and e-commerce—enables manufacturing throughput and precision that are difficult for competitors using older production techniques to replicate.
What growth costs
It invests in its Wilsonville, Oregon facility and biopharma sales force to address an accumulated deficit of $1,319.6 million by expanding into drug discovery.
The company must fund the transition from selling basic DNA fragments to offering higher-value services like antibody libraries and biologic drug discovery. This involves maintaining a specialized sales force and optimizing the utilization of its manufacturing facility in Wilsonville, Oregon.
Ongoing reinvestment is required to reach profitability, as the company has incurred significant losses since inception, resulting in a total accumulated deficit of $1,319.6 million as of late 2025.
What could damage it
Revenue and production capacity would be impaired by the loss of its single-source supplier for a critical component used in the synthesis process.
The manufacturing process is dependent on a single-source supplier for a critical component. While management notes that alternative suppliers exist and they maintain a reserve, any disruption in this supply chain would directly cause production delays.
Because the silicon-based DNA writing technology is the core of its competitive advantage, any inability to secure this component would prevent the company from fulfilling orders and maintaining its market position against competitors.
About Twist Bioscience Corporation
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc and Lilly TuneLab. The company was incorporated in 2013 and is headquartered in South San Francisco, California.